(Q42528919)

English

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

scientific article published on January 1997

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

B Chevallier

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

P Cappelaere

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

T Splinter

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

M Fabbro

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

J L Wendling

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

L Cals

6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

G Catimel

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

M Giovannini

8

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

D Khayat

9

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

P Bastit

10

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

N Claverie

11

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

publication date

1 January 1997

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Supportive Care in Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

22-30

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of chemotherapy-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current issues in the management of nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrapyramidal reactions with metoclopramide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nausea and vomiting as major complications of cancer chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serotonin antagonists: a new class of antiemetic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9010986

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S005200050036

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42528919&oldid=1960870045"